Cortisone-induced gigantomastia during chemotherapy

Gigantomastia remains a poorly defined condition with no standardized diagnostic criteria. Most cases involve breast enlargement severe enough to require surgical intervention. The condition is often linked to hormonal fluctuations during puberty or pregnancy. Autoimmune diseases have also been reported as potential contributors. Medications such as penicillamine and cyclosporine have been rarely associated with gigantomastia. However, the exact mechanisms behind these associations are not well understood. Prior research has not established a clear link between cortisone and gigantomastia. This gap motivated the investigation of a new case involving cortisone use during cancer treatment.

This case aims to describe the first reported instance of gigantomastia linked to cortisone use. The patient had undergone surgery for ovarian cancer and was receiving chemotherapy. The goal was to explore the possible connection between cortisone and breast enlargement. The study also aimed to propose a possible explanation for this rare occurrence. Researchers wanted to highlight the need for awareness among clinicians. The motivation stemmed from the lack of prior documentation on this association. The case provides a unique opportunity to examine cortisone’s role in breast tissue changes. The study’s findings could help guide future clinical management of similar cases.

The study involved a retrospective analysis of a single patient’s medical history. The patient had undergone hysterectomy and bilateral adnexectomy for ovarian cancer. Chemotherapy cycles followed the surgical procedures. Cortisone was administered as part of the treatment regimen. Researchers collected clinical data on breast size and symptoms. They also reviewed the patient’s hormonal and metabolic status. A clinic-based evidence approach was used to assess the timeline of breast enlargement. A metabolic theory was proposed to explain the possible mechanism behind the condition.

The patient developed gigantomastia after cortisone administration during chemotherapy. The breast enlargement was severe enough to require surgical intervention. The reported weight of the removed tissue was within the gigantomastia range. The condition occurred in the absence of typical hormonal triggers like pregnancy. The cortisone use was the only new pharmacological agent introduced at the time. The researchers noted a direct temporal relationship between cortisone and breast growth. No other medications were identified as potential causes. The proposed metabolic theory suggests cortisone may influence breast tissue proliferation.

The authors suggest that cortisone may play a role in the development of gigantomastia. The case highlights the need for further investigation into cortisone’s effects on breast tissue. The proposed metabolic theory offers a possible explanation for the observed phenomenon. The findings emphasize the importance of monitoring breast changes in patients receiving cortisone. The study does not confirm causation but proposes a plausible association. The authors recommend increased awareness among clinicians treating cancer patients. The case adds to the limited literature on cortisone-related side effects. The report serves as a reference for future clinical decision-making.